Antibody Against SARS-CoV-2 Joined Best Inventions of 2022
AstraZeneca recently announced its long-acting monoclonal antibody (mAbs) was recently added to the list of Best Inventions of 2022 by TIME.
EVUSHELD™ is the first and only long-acting mAbs to receive authorization in the U.S. to prevent COVID-19 in immunocompromised people.
"Immunocompromised individuals have lived a very different pandemic experience than most of us," said Joris Silon, U.S. Country President, BioPharmaceutical Business Unit, AstraZeneca, in a press release on November 10, 2022.
"EVUSHELD™ is an important scientific innovation, but it has also been a beacon of hope for those who have felt left behind in our return to normalcy."
"The inclusion of EVUSHELD in TIME's Best Inventions list is a testament to our commitment to advance the science of immune therapies to support this vulnerable population."
Of the new list, TIME's editors write: "The result is a list of 200 groundbreaking inventions (and 50 special mention inventions) – including life-mapping artificial intelligence, diamonds made from excess carbon in the air and the most powerful telescope ever – that are changing how we live, work, play and think about what's possible."
See the complete list of TIME winners here: time.com/best-inventions-2022.
According to the U.S. NIH, mAbs products can effectively prevent infections caused by the SARS-CoV-2 beta coronavirus, including Omicron BA.x subvariants.
Throughout the pandemic, mAbs became readily accessible, even on main-street.
The Journal of the American Pharmacists Association found that by August 2022, pharmacists had provided more than 100,000 mAbs treatments for COVID-19.
EVUSHELD was also authorized in the EU, Japan, and many other countries for people whose immune systems were compromised by chemotherapy or other immunosuppressive drugs or because they have hematologic malignancies, advanced or untreated HIV, a primary immune deficiency, or they have had a solid organ or bone marrow transplant.
Furthermore, a recent study conducted in Pittsburg, PA, found that mAbs treatment was safe for pregnant women.
This peer-reviewed Original Research found pregnant women with mild to moderate COVID-19, adverse events after mAb treatment were mild and rare.
And there was no difference in obstetric-associated safety outcomes between the mAb treatment and no treatment among persons who delivered a child.
And the WHO's Living guideline: Drugs to prevent COVID-19 can be accessed online.
Other mAbs news is posted at PrecisionVaccinations.com/Antibody.
PrecisionVaccinations publishes fact-checked, research-based news manually curated for mobile readers.
Updated with citations on Nov. 15, 2022.